Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Bayer Aktiengesellschaft American Depositary Shares (OP: BAYRY)
108.70 USD  UNCHANGED
Official Closing Price  /  Updated: 8:10 PM EDT, May 23, 2013  /  Add to My Watchlist      
View: Quote News Research
All news about Bayer Aktiengesellschaft American Depositary Shares
 
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Pipeline Progress At Regeneron
April 08, 2011
Recently, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and partner Bayer (BAYRY) announced the commencement of a phase III study (VIVID-DME) to evaluate the safety and effectiveness of their VEGF... Read More
category RHHBY , Australia , REGN , and 9 more.
from DailyMarkets.com
Optimer Partners Cubist For Dificid
April 07, 2011
Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) recently announced an exclusive two-year agreement with Cubist Pharmaceuticals Inc. (NASDAQ:CBST) to co-promote its lead pipeline candidate, fidaxomicin, to... Read More
category RHHBY , OPTR , External Research , and 10 more.
from DailyMarkets.com
(JNJ) Bayer Presents Xarelto Blood Thinner Data
April 07, 2011
Recently, Germany’s Bayer (BAYRY) presented mixed data regarding its blood thinner Xarelto (rivaroxaban) for preventing venous thromboembolism (VTE) in hospitalized ill patients. Data from the... Read More
category JNJ , Sanofi/Aventis , AF , and 5 more.
from Stock Blog Hub
Xarelto Data Presented By Bayer
April 06, 2011
Recently, Germany’s Bayer (BAYRY) presented mixed data regarding its blood thinner Xarelto (rivaroxaban) for preventing venous thromboembolism (VTE) in hospitalized ill patients. Data from the... Read More
category Eurozone , SNY , jnj , and 5 more.
from DailyMarkets.com
Optimer Drug To Face FDA Panel
March 28, 2011
The new drug application (NDA) of Optimer Pharmaceuticals Inc.’s (NASDAQ:OPTR) lead pipeline candidate, fidaxomicin, is due to be reviewed by a US Food and Drug Administration (FDA) Advisory Committee... Read More
category RHHBY , OPTR , External Research , and 10 more.
from DailyMarkets.com
Good News For Bristol-Myers
March 21, 2011
Recently, an advisory panel of the European Medicines Agency (EMA) delivered a positive opinion regarding the European approval of Bristol-Myers’ (NYSE:BMY) blood-thinner Eliquis (apixaban). Eliquis,... Read More
category Eurozone , USA , Stocks , and 5 more.
from DailyMarkets.com
Weekly Economic and EPS Report Schedule
March 21, 2011
from Wall Street Greek
Mylan Rests At Neutral
March 18, 2011
We have maintained our Neutral recommendation on Mylan Inc. (NYSE:MYL) with a target price of $23.00 after appraising fourth quarter and fiscal year 2010 financial results. Mylan’s fourth quarter 2010... Read More
category TEVA , External Research , Contributor , and 7 more.
from DailyMarkets.com
Onyx Pharma Upgraded to Neutral
March 18, 2011
We have upgraded our rating on Onyx Pharmaceuticals, Inc. (ONXX) to Neutral from Underperform following the release of fourth quarter and fiscal year 2010 financial results. We were pleased to see an... Read More
category updowngrades , Latest , Wall Street , and 1 more.
from Wall Street Pit
Regeneron Keeps Neutral Rec
March 09, 2011
We are maintaining our Neutral recommendation on Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) with a target price of $38.00. Regeneron, a biopharmaceutical company, focuses on the discovery,... Read More
category REGN , External Research , Contributor , and 6 more.
from DailyMarkets.com
EVOL, SGMS, BAYRY, GHDX, ARW: Increased Volatility Due to Recent News Announcements
March 09, 2011
from EmailWire.Com Press Releases
Analyst Interviews: Pharmaceutical Industry Outlook
March 02, 2011
The pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage... Read More
category UK , GENZ , ABT , and 21 more.
from DailyMarkets.com
Revenues Rise At Bayer
March 01, 2011
Bayer AG’s (BAYRY) earnings per share during the fourth quarter of 2010 came in at €0.95 (approx $1.29) compared to €0.90 (approx. $1.33) in the year-ago period. Bayer incurred €825 million towards... Read More
category UK , jnj , USA , and 4 more.
from DailyMarkets.com
Updates, advisories and surprises
February 28, 2011
A roundup of the latest corporate earnings reports and what companies are saying about future quarters. Read More
category Earnings , Stoxx600 , UKX , and 9 more.
from MarketWatch
Q4 Loss At Regeneron Narrows
February 18, 2011
Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) fourth quarter 2010 net loss of 17 cents per share was narrower than the Zacks Consensus Estimate of a net loss of 32 cents. The company suffered a loss... Read More
category AZN , REGN , SNY , and 5 more.
from DailyMarkets.com
Watson Pharma Outperforms
February 15, 2011
Watson Pharmaceuticals Inc.’s  (NYSE:WPI) fourth quarter 2010 earnings (excluding special items) of $0.93 per share were in line with the Zacks Consensus Estimate and $0.08 above the year-ago earnings.... Read More
category SHPGY , jnj , USA , and 6 more.
from DailyMarkets.com
Orphan Status For Bayer Candidate
February 10, 2011
Recently, Germany’s Bayer (BAYRY) announced that its cancer candidate regorafenib (BAY 73-4506) has been granted orphan drug designation by the US Food and Drug Administration (FDA). The status has... Read More
category UK , Eurozone , jnj , and 5 more.
from DailyMarkets.com
Zacks Bull and Bear of the Day Highlights: Suntech Power Holdings, Bayer AG, Manpower, Macy and Ford
February 07, 2011
from PR Newswire
Inside Wall Street: Every January, It's a Four-Day Health Care Fest in San Francisco
January 21, 2011
From Jan. 10 to 13, thousands of investment pros and corporate chiefs flocked to the St. Francis Hotel for standing-room-only annual health care conference hosted by JPMorgan Chase. But two other,... Read More
category RXII , Jamie Dimon , biotech stocks , and 14 more.
from DailyFinance.com
Bayer?s Rivaroxaban submitted for EU marketing authorisation in Stroke Prevention in patients with Atrial Fibrillation as well as for the treatment of Deep Vein Thrombosis (DVT)
January 07, 2011
Bayer has submitted an application for marketing authorization to the European Medicines Agency (EMA) for the oral anticoagulant rivaroxaban in stroke prevention in patients with atrial fibrillation... Read More
category Application , Major Drugs , HealthCare
from 1888PressRelease - Full Feed
Biotech Stocks Will be Fueled by Takeovers in 2011
December 28, 2010
While a number of companies are on the verge of hitting the market with exciting new drug products or medical treatments, the biggest 2011 profits for investors in the biotech stocks are more likely to... Read More
category Stocks
from Money Morning
Neutral On Optimer Pharma
December 15, 2010
We are maintaining our Neutral recommendation on Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) with a target price of $12.00. Headquartered in San Diego, California and founded in 1998, Optimer... Read More
category OPTR , External Research , Contributor , and 6 more.
from DailyMarkets.com
Bayer Inks Deal
December 14, 2010
Recently, the Crop Science segment of Bayer (BAYRY) inked a five-year deal with the privately held biotechnology company Evogene Ltd. to improve wheat seeds. The deal will focus on improvements... Read More
category Stocks , External Research , Contributor , and 1 more.
from DailyMarkets.com
(JNJ) Bayer and Johnson & Johnson Blood Thinner Xarelto Performs Well
December 13, 2010
Germany’s Bayer (BAYRY) received a huge boost when its blood thinner Xarelto (rivaroxaban), co-developed with Johnson & Johnson (JNJ), fared well in a pivotal, double-blind, late-stage study... Read More
category Pfizer Inc/ , JNJ , Healthcare , and 5 more.
from Stock Blog Hub
EU Label Expansion For Sutent
December 03, 2010
Pfizer Inc. (NYSE:PFE) recently announced that it received approval from the European Commission for an additional indication for cancer drug Sutent. Sutent gained approval for the treatment of... Read More
category Eurozone , Stocks , External Research , and 3 more.
from DailyMarkets.com
Drugs stocks tepid; Regeneron rallies
November 22, 2010
Regeneron shares rally on positive data for its new eye medication. Read More
category REGN , Biotechnology , Analyst , and 14 more.
from MarketWatch
Somaxon paces decliners in drug sector
November 19, 2010
Somaxon is the drug sector’s lead decliner in early trading Friday after it priced a public stock offering substantially below Thursday’s closing price. Read More
category Market News , DRG , Biotechnology , and 12 more.
from MarketWatch
Ardea Biosciences Evenly Poised
November 16, 2010
We are maintaining our Neutral recommendation on Ardea Biosciences Inc. (NASDAQ:RDEA) with a target price of $23.00. Ardea Biosciences, headquartered in San Diego, CA, focuses on the discovery and... Read More
category NVS , SVNT , RDEA , and 5 more.
from DailyMarkets.com
Third Quarter Loss Widens At Ardea
November 12, 2010
Ardea Biosciences Inc.’s (NASDAQ:RDEA) third quarter 2010 net loss of $18.2 million or 79 cents per share was higher than the year-ago loss of $2.5 million or 13 cents per share and the Zacks Consensus... Read More
category RDEA , Stocks , External Research , and 2 more.
from DailyMarkets.com
Seattle Genetics (Nasdaq: SGEN) Trepidation
November 03, 2010
category SGEN , Stock/Picks , stock news , and 1 more.
from Wall Street Greek
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here